CM
CLDX icon

Crestline Management’s Celldex Therapeutics CLDX Stock Holding History

Crestline Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-295,354
Closed -$7.46M – 117
2024
Q4 		$7.46M Buy
295,354
+157,366
+114% +$4.28M 0.25% 87
2024
Q3 		$4.69M Buy
137,988
+52,637
+62% +$2.01M 0.24% 112
2024
Q2 		$3.16M Buy
85,351
+16,062
+23% +$606K 0.25% 113
2024
Q1 		$2.91M Buy
69,289
+2,046
+3% +$84K 0.26% 113
2023
Q4 		$2.67M Buy
67,243
+4,133
+7% +$122K 0.23% 121
2023
Q3 		$1.74M Buy
63,110
+21,383
+51% +$670K 0.2% 114
2023
Q2 		$1.42M Buy
41,727
+11,465
+38% +$386K 0.15% 124
2023
Q1 		$1.09M Sell
30,262
-6,103
-17% -$263K 0.13% 123
2022
Q4 		$1.62M Sell
36,365
-3,628
-9% -$130K 0.24% 80
2022
Q3 		$1.12M Buy
39,993
+1,900
+5% +$58.2K 0.15% 104
2022
Q2 		$1.03M Buy
38,093
+5,998
+19% +$174K 0.13% 121
2022
Q1 		$1.09M Buy
+32,095
New +$1.03M 0.13% 135

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crestline Management's CLDX Position: Q1 2025 in Review

Crestline Management sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 295,354 shares — an estimated $7.46M sold.

Crestline Management first reported a position in CLDX in Q1 2022 and held it in 12 quarters. The position peaked at $7.46M in Q4 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • Crestline Management reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 295,354 Celldex Therapeutics shares in Q1 2025, an estimated $7.46M.
  • Crestline Management first reported a position in Celldex Therapeutics in Q1 2022 and held it in 12 quarters.
  • Crestline Management's Celldex Therapeutics position peaked at $7.46M in Q4 2024.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.